



# MARKET RELEASE

1 September 2014

**Antisense Therapeutics Limited**

**TRADING HALT**

The securities of Antisense Therapeutics Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 3 September 2014 or when the announcement is released to the market.

Security Code: ANP

Kate Kidson  
Principal Adviser, Listings Compliance (Melbourne)

Monday 01 September 2014

Kate Kidson  
Principal Advisor  
Listings Compliance (Melbourne)  
ASX Compliance Pty Limited

Email: [kate.kidson@asx.com.au](mailto:kate.kidson@asx.com.au)

Dear Kate,

### **Request for Trading Halt**

In accordance with ASX listing Rule 17.1, the Directors of Antisense Therapeutics Limited (“the Company”) requests an immediate trading Halt in respect of its securities (ASX:ANP and ASX:ANPO).

In requesting the trading halt the Company provides the following information:

- The trading halt is requested pending an announcement on the results of ANP’s ATL1103 Acromegaly Phase II clinical trial results;
- The requested trading halt is to remain in place until, the earlier of, the release of the Clinical Trial results or the opening of the market of Wednesday 3<sup>rd</sup> September,
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely



Phillip Hains  
Company Secretary